Compound | Tissue and Receptor Subtype | ||||
---|---|---|---|---|---|
Rat Vas Deferens α1A | Canine Prostate α1A | Rabbit Urethra α1L | Rat Spleen α1B | Rat Aorta α1D | |
Fiduxosin2-a | |||||
pA2(±S.E.M.) | 9.62 (±0.44) | 8.51 (±0.23) | 7.58 (±0.19) | 7.08 (±0.07) | 8.92 (±0.86) |
Slope (±S.E.M.) | 0.83 (±0.07) | 0.80 (±0.05) | 0.92 (±0.13) | 0.90 (±0.05) | 0.78 (±0.08) |
[n] | [18] | [20] | [15] | [14] | [20] |
Terazosin2-b | |||||
pA2(±S.E.M.) | 8.04 (±0.45) | 7.44 (±0.24) | 6.77 (±0.30) | 8.60 (±0.46) | 8.65 (±0.29) |
Slope (±S.E.M.) | 0.83 (±0.17) | 0.79 (±0.09) | 0.99 (±0.07) | 0.94 (±0.14) | 0.99 (±0.13) |
[n] | [12] | [35] | [13] | [12] | [9] |
Tamsulosin2-c | |||||
pA2(±S.E.M.) | 9.47 (±0.21) | 9.54 (±0.17) | 8.86 (±0.22) | 9.69 (±0.44) | 10.6 (±0.43) |
Slope (±S.E.M.) | 1.06 (±0.14) | 1.12 (±0.08) | 1.41 (±0.26) | 0.84 (±0.15) | 0.94 (±0.11) |
[n] | [22] | [20] | [8] | [16] | [10] |
Isolated smooth muscle strips or rings were incubated in tissue baths in the presence or absence of various concentrations of fiduxosin and standard α1-adrenoceptor antagonists, as described underExperimental Procedures.
↵2-a One-way analysis of variance indicated the following potency order of statistically significant differences for fiduxosin: rat vas deferens > rat aorta ≅ canine prostate > rabbit urethra > rat spleen α1-adrenoceptor antagonism.
↵2-b One-way analysis of variance indicated the following potency order of statistically significant differences for terazosin: rat aorta ≅ rat spleen > rat vas deferens > canine prostate > rabbit urethra α1-adrenoceptor blockade.
↵2-c One-way analysis of variance indicated the following potency order of statistically significant differences for tamsulosin: rat aorta > canine prostate > rabbit urethra, but canine prostate ≅ rat vas deferens ≅ rat spleen and rat vas deferens ≅ rat spleen ≅ rabbit urethra α1-adrenoceptor antagonism.